If the strategy is to bring PSI-7977 monotherapy to market as a first generation oral compound there are clearly advantages to this line of thinking. By November PSI-7977 will have been through extensive phase 2 testing and it and will move much quicker through late stage testing than the dual nuke combination. That is if monotherapy is a viable option. The lack of interferon should also help expedite the process.
News 
Market Data 
Discover 
